Literature DB >> 1710947

What value is given to quality of life assessment by health professionals considering response to palliative chemotherapy for advanced cancer?

I R Gough1, L I Dalgleish.   

Abstract

A study was designed to obtain information on the importance of quality of life assessment (QL) during palliative chemotherapy. A questionnaire was answered by 542 health professionals (392 general practitioners, 20 specialist oncologists, and 130 oncology nurses). In both simulated patient situations and multiple-choice questions, all groups rated QL higher than other standard methods of assessment. General practitioners and oncologists appeared to weight the assessment criteria more equally than nurses who gave strong emphasis to QL. In the simulated patient situation, there was a small degree of interaction between QL and other assessment criteria. However, the analysis showed that QL was regarded as an independent variable and was considered to be the most important objective of palliative chemotherapy for advanced cancer.

Entities:  

Mesh:

Year:  1991        PMID: 1710947     DOI: 10.1002/1097-0142(19910701)68:1<220::aid-cncr2820680140>3.0.co;2-h

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

1.  Oncologists' use of quality of life information: results of a survey of Eastern Cooperative Oncology Group physicians.

Authors:  A Bezjak; P Ng; R Skeel; A D Depetrillo; R Comis; K M Taylor
Journal:  Qual Life Res       Date:  2001       Impact factor: 4.147

2.  Continence specialists use of quality of life information in routine practice: a national survey of practitioners.

Authors:  Kirstie L Haywood; Andrew M Garratt; Sandra Carrivick; Joanne Mangnall; Suzanne M Skevington
Journal:  Qual Life Res       Date:  2009-03-07       Impact factor: 4.147

3.  The use of quality of life data in clinical practice.

Authors:  J Morris; D Perez; B McNoe
Journal:  Qual Life Res       Date:  1998-01       Impact factor: 4.147

4.  Criterion-based validation of the EORTC QLQ-C36 in advanced melanoma: the CIPS questionnaire and proxy raters.

Authors:  V Sigurdardóttir; Y Brandberg; M Sullivan
Journal:  Qual Life Res       Date:  1996-06       Impact factor: 4.147

5.  Cancer patients who refuse treatment.

Authors:  S A Huchcroft; T Snodgrass
Journal:  Cancer Causes Control       Date:  1993-05       Impact factor: 2.506

6.  Feasibility and acceptance of electronic monitoring of symptoms and syndromes using a handheld computer in patients with advanced cancer in daily oncology practice.

Authors:  D Blum; D Koeberle; A Omlin; J Walker; R Von Moos; W Mingrone; S deWolf-Linder; S Hayoz; S Kaasa; F Strasser; K Ribi
Journal:  Support Care Cancer       Date:  2014-04-05       Impact factor: 3.603

7.  Integrating health-related quality of life findings from randomized clinical trials into practice: an international study of oncologists' perspectives.

Authors:  Julie Rouette; Jane Blazeby; Madeleine King; Melanie Calvert; Yingwei Peng; Ralph M Meyer; Jolie Ringash; Melanie Walker; Michael D Brundage
Journal:  Qual Life Res       Date:  2014-11-29       Impact factor: 4.147

8.  Individualized quality of life, standardized quality of life, and distress in patients undergoing a phase I trial of the novel therapeutic Reolysin (reovirus).

Authors:  Linda E Carlson; Barry D Bultz; Donald G Morris
Journal:  Health Qual Life Outcomes       Date:  2005-01-27       Impact factor: 3.186

9.  Electronic monitoring of symptoms and syndromes associated with cancer: methods of a randomized controlled trial SAKK 95/06 E-MOSAIC.

Authors:  David Blum; Dieter Koeberle; Karin Ribi; Shu-Fang Hsu Schmitz; Urs Utiger; Dirk Klingbiel; Florian Strasser
Journal:  BMC Palliat Care       Date:  2012-09-24       Impact factor: 3.234

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.